CD274 and neoplasm: Several recent examples have demonstrated the potential for various types of oncolytic viruses expressing immune checkpoint inhibitors such as anti-PDCD1 (PD-1), anti-CD274 (PD-L1), and anti-CTLA4 (Du et al., 2014; Kleinpeter et al., 2016; Tanoue et al., 2017), as well as other anti-tumor antibodies (Adelfinger et al., 2015; Liikanen et al., 2016; Fajardo et al., 2017).